When Washington Changes the Rules, Patients Feel It First

A product can be available to a patient today and pushed into legal uncertainty tomorrow. That is not an abstract policy problem. It is a patient-care problem.

I recently served as a panelist for Navigating Regulatory Uncertainty: Hemp, Cannabis, and Federal Policy. We discussed changing federal definitions, intoxicating hemp-derived products, high-potency concentrates, synthetic cannabinoids, patient access, and the voices of Tribal Nations.

The loudest arguments usually come from government and industry. The patient is too often missing from the room.

Some hemp products are poorly labeled, aggressively marketed, and sold without meaningful age controls or consistent testing. That is unacceptable. A label should tell consumers what is in the package, how much is in one serving, and whether the product has been tested for contaminants. Children should never be the marketing target.

But fixing a loophole with a legislative hammer creates a different danger. Broad restrictions can remove products that patients use responsibly, punish legitimate businesses, and force consumers back into an unregulated market. Public safety is not served when regulation ignores real-world behavior.

We also need to stop treating every cannabinoid as though it were the same. A plant-derived CBD preparation, a chemically converted intoxicant, a high-potency concentrate, and a laboratory-created street drug do not carry identical risks. Good policy recognizes those differences. Bad policy hides them under one label.

High-potency products deserve honest scrutiny. Greater exposure can mean greater impairment and greater risk, especially for young people and individuals vulnerable to anxiety, psychosis, cardiovascular complications, or problematic use. A responsible cannabis movement must be willing to say that plainly.

Patient protection and patient access are not opposing goals. We can demand accurate labels, independent testing, child-resistant packaging, clear potency and serving-size standards, and age restrictions while preserving access to products that meet legitimate standards.

Tribal Nations must also be included before decisions are made, not acknowledged afterward. Sovereign Nations have their own healthcare, cultural, legal, agricultural, and economic interests. As a member of the Governing Board of Directors of the Indigenous Cannabis Industry Association, my role is not to speak for Tribal Nations. It is to insist that they have the opportunity to speak for themselves.

Clinicians belong in this conversation because we see what policy looks like after it reaches the examination room. We see the patient who does not understand the label, the interaction no one discussed, the product that changed without warning, and the person who is afraid to tell a physician what they are using.

The right federal framework is neither a free-for-all nor a return to blanket prohibition. It is a system that protects children, holds manufacturers accountable, preserves responsible adult and medical access, respects Tribal sovereignty, and follows evidence instead of slogans.

When the rules change, patients feel it first. Their health must be part of the decision before the law is written, not after the damage is done.